Safety study of crenolanib, a Type I FLT3 inhibitor, with cytarabine/daunorubicin or cytarabine/idarubicin induction and high-dose cytarabine consolidation in newly diagnosed FLT3+ AML Meeting Abstract

   


Authors: Wang, E.; Stone, R.; Tallman, M.; Thompson, J.; Ontiveros, E.; Olson, G.; Galinsky, I.; Pond, B.; Uchida, A.; Urity, V.; Xhori, O.; Macaraeg, M.; Vusirikala, M.; Patel, P.; Walter, R.; Collins, R.
Abstract Title: Safety study of crenolanib, a Type I FLT3 inhibitor, with cytarabine/daunorubicin or cytarabine/idarubicin induction and high-dose cytarabine consolidation in newly diagnosed FLT3+ AML
Meeting Title: 21st Congress of the European Hematology Association (EHA)
Journal Title: Haematologica
Volume: 101
Issue: Suppl. 1
Meeting Dates: 2016 Jun 9-12
Meeting Location: Copenhagen, Denmark
ISSN: 0390-6078
Publisher: Ferrata Storti Foundation  
Date Published: 2016-06-01
Start Page: 41
Language: English
ACCESSION: WOS:000379484600089
PROVIDER: wos
PMCID: PMC4894295
Notes: Meeting Abstract: P186 -- Source: Wos